BioSpace News Archive

Nordic Nanovector ASA announces that it will amend the trial protocol for its PARADIGME trial to broaden the inclusion criteria and expand the pool of eligible patients with the aim of increasing the present rate of enrolment.

The leader in self-monitoring of blood glucose in France will distribute Mallya connected device to pharmacists and will integrate it into its Roche Diabetes digital ecosystem.

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, announced that it expects to consider additional capital raising options this year, which could include an initial public offering in the United States.

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, announced the closing of a $120 million extended Series C financing.

Participants will be randomised to receive the low molecular weight Heparin enoxaparin or current standard of care for up to 3 weeks from the time of diagnosis

Ipsos MORI survey: 72% of farmers have significant concerns about the impact climate change will have on their ability to grow food over the next five years

Hansa Biopharma will publish its interim report for January-June 2020 at 8:00 a.m. CET on July 16, 2020.

During June 2020, the registered number of shares and votes in Moberg Pharma AB has increased due to conversion of convertible notes issued pursuant to the financing agreement entered into between the Company and Nice & Green S.A. on March 23rd, 2020.

Orexo AB, announces positive results from its human pharmacokinetic study of OX125.

Oncopeptides AB announces that the Company submits a New Drug Application to the U.S. FDA, for accelerated approval of melflufen in combination with dexamethasone for the treatment of adult patients with multiple myeloma whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody.